A growing number of US state legislatures are advancing restrictions on cosmetic ingredients classified as toxic, a trend that exposes long-standing gaps in the federal regulatory framework for personal care products. The activity, flagged by trade publication Personal Care Insights, frames the state-level response as a direct consequence of the federal government's limited authority over cosmetic ingredient safety.

Why the federal framework is seen as inadequate

Industry observers have long argued that the US Food and Drug Administration lacks the pre-market approval authority that other major markets exercise over cosmetic ingredients. The Modernization of Cosmetics Regulation Act of 2022 strengthened FDA's post-market tools, including facility registration, mandatory recall power and forthcoming fragrance allergen disclosure, but stopped short of a federal negative list or positive list for restricted substances.

That structural gap is the political opening state legislators continue to use. Without comprehensive federal action, advocacy groups and state lawmakers are pursuing their own restrictions, warning-label regimes and ingredient bans — a pattern that has accelerated in successive legislative sessions.

What this means for formulators and procurement

For product developers, the practical consequence is a matrix of state-by-state chemical regulations that must be checked alongside federal requirements. A single national SKU may need to satisfy divergent lists of restricted substances, varying warning-label formats and inconsistent contaminant thresholds depending on destination market.

Procurement teams face parallel pressure. Raw materials approved under federal law can still face state-level sales or distribution bans, which means buyers often maintain dual specifications depending on shipping destination. The cost — in reformulation cycles, stability and challenge testing, and label redesigns — typically runs several months per affected SKU.

Treatment-menu and retail implications

For salon operators, spa clinicians and estheticians, the fragmented landscape translates into uneven product availability. Professional treatment lines sold in restricted states may differ from those available in neighboring jurisdictions, pushing multi-location operators toward nationwide-compatible formulations or parallel inventories.

Retail buyers carry the same verification load: every SKU on the shelf must be checked against the chemical restrictions of every state in which the chain operates, including private-label lines sourced through third-party manufacturers. Chains with national footprints increasingly centralize that work through regulatory affairs teams rather than store-level buyers.

The compliance workload

Brand owners report that tracking state-level chemical lists now consumes a disproportionate share of regulatory affairs bandwidth, particularly when adjacent states adopt different lists on overlapping timelines. The result is reformulation work that cannot be batched, separate label stocks per state, and growing reliance on regulatory databases that map ingredient status across all 50 states.

Independent brands without in-house regulatory staff face a sharper version of the same problem and increasingly route their product development through contract manufacturers that can absorb the compliance cost across multiple clients.

The direction of travel

In the absence of comprehensive federal action, US cosmetic regulation is fragmenting along state lines. The cost of that fragmentation is being absorbed by formulators, contract manufacturers and brand owners, and ultimately passed through to professional buyers and end consumers.

The next data points to watch are the outcomes of current state legislative sessions, any FDA implementation guidance issued under MoCRA, and any state-level enforcement actions brought against manufacturers whose formulations include ingredients on state restriction lists.